AMLX Class Action Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline – April 9, 2024 – in Amylyx Pharmaceuticals, Inc. Class Action
21. März 2024 18:06 ET
|
Robbins LLP
Robbins LLP is investigating the allegations that Amylyx Pharmaceuticals, Inc. (AMLX) misled investors regarding RELYVRIO's commercial prospects.
AMLX STOCK NEWS: Lead Plaintiff Deadline is Approaching in Class Action Against Amylyx Pharmaceuticals, Inc.; Contact Robbins LLP for Information
05. März 2024 16:16 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Amylyx Pharmaceuticals, Inc. (AMLX) Misled Investors Regarding the Viability of its Drug for Treating ALS
AMLX Class Action Alert: Robbins LLP Reminds Shareholders of Lead Plaintiff Deadline in the Class Action Against Amylyx Pharmaceuticals, Inc.
20. Februar 2024 15:18 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations Against Amylyx Pharmaceuticals Inc.
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)
12. Februar 2024 22:28 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations Against Amylyx Pharmaceuticals, Inc.